R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high ...
Financing and global licensing deal to accelerate phase 2b development of AP306 R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company looks to grow from ...
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE)-- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with ...
March 17 (Reuters) - R1 Therapeutics said on Tuesday it had launched operations with a $77.5 million Series A funding round and an exclusive license to develop and commercialize a drug for high ...
Forbes contributors publish independent expert analyses and insights. Sasha Lekach covers electric vehicles and vehicle technology. Rivian finally gave more details on its next, smaller all-electric ...
Gaming PCs This AMD RX 9070 XT and 7800X3D gaming PC is somehow beating last year's prices at $1,750 Handheld Gaming PCs Best handheld gaming PC in 2026: my recommendations for the best portable ...
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results